Search

Your search keyword '"Pediatric Emergency Research Network–COVID-19 Study Team"' showing total 4 results
Start Over Author "Pediatric Emergency Research Network–COVID-19 Study Team"
4 results on '"Pediatric Emergency Research Network–COVID-19 Study Team"'

1. Corticosteroids and Other Treatments Administered to Children Tested for SARS-CoV-2 Infection in Emergency Departments.

Author

Freedman, Stephen B, Kuppermann, Nathan, Funk, Anna L, Kim, Kelly, Xie, Jianling, Tancredi, Daniel, Dalziel, Stuart R, Neuman, Mark I, Mintegi, Santiago, Plint, Amy C, Gómez-Vargas, Jessica, Finkelstein, Yaron, Ambroggio, Lilliam, Klassen, Terry P, Salvadori, Marina, Malley, Richard, Payne, Daniel C, Florin, Todd A, and Pediatric Emergency Research Network-COVID-19 Study Team

Subjects
Pediatric Emergency Research Network-COVID-19 Study Team, Humans, Adrenal Cortex Hormones, Nucleic Acids, Cross-Sectional Studies, Adolescent, Child, Emergency Service, Hospital, SARS-CoV-2, COVID-19 Drug Treatment, COVID-19, adrenal cortex hormones, child, hospitalized, emergency service, hospital, Emerging Infectious Diseases, Pediatric, Vaccine Related, Prevention, Clinical Trials and Supportive Activities, Biodefense, Clinical Research, Lung, Infectious Diseases, Respiratory, child, hospitalized, emergency service, hospital, Paediatrics and Reproductive Medicine, Pediatrics
Abstract

ObjectiveWe sought to determine if corticosteroid administration is associated with a SARS-CoV-2 nucleic acid test-positive result and to describe therapies administered to SARS-CoV-2 infected children.MethodsWe collected cross-sectional data from participants recruited in 41 pediatric emergency departments (ED) in 10 countries between March 2020 and June 2021. Participants were

Published
2022

2. Outcomes of SARS-CoV-2-Positive Youths Tested in Emergency Departments: The Global PERN-COVID-19 Study.

Author

Pediatría, Pediatria, Pediatric Emergency Research Network-COVID-19 Study Team, Mintegi Raso, Santiago, Pediatría, Pediatria, Pediatric Emergency Research Network-COVID-19 Study Team, and Mintegi Raso, Santiago

Abstract

[EN] Importance: Severe outcomes among youths with SARS-CoV-2 infections are poorly characterized. Objective: To estimate the proportion of children with severe outcomes within 14 days of testing positive for SARS-CoV-2 in an emergency department (ED). Design, Setting, and Participants: This prospective cohort study with 14-day follow-up enrolled participants between March 2020 and June 2021. Participants were youths aged younger than 18 years who were tested for SARS-CoV-2 infection at one of 41 EDs across 10 countries including Argentina, Australia, Canada, Costa Rica, Italy, New Zealand, Paraguay, Singapore, Spain, and the United States. Statistical analysis was performed from September to October 2021. Exposures: Acute SARS-CoV-2 infection was determined by nucleic acid (eg, polymerase chain reaction) testing. Main Outcomes and Measures: Severe outcomes, a composite measure defined as intensive interventions during hospitalization (eg, inotropic support, positive pressure ventilation), diagnoses indicating severe organ impairment, or death. Results: Among 3222 enrolled youths who tested positive for SARS-CoV-2 infection, 3221 (>99.9%) had index visit outcome data available, 2007 (62.3%) were from the United States, 1694 (52.6%) were male, and 484 (15.0%) had a self-reported chronic illness; the median (IQR) age was 3 (0-10) years. After 14 days of follow-up, 735 children (22.8% [95% CI, 21.4%-24.3%]) were hospitalized, 107 (3.3% [95% CI, 2.7%-4.0%]) had severe outcomes, and 4 children (0.12% [95% CI, 0.03%-0.32%]) died. Characteristics associated with severe outcomes included being aged 5 to 18 years (age 5 to <10 years vs <1 year: odds ratio [OR], 1.60 [95% CI, 1.09-2.34]; age 10 to <18 years vs <1 year: OR, 2.39 [95% CI 1.38-4.14]), having a self-reported chronic illness (OR, 2.34 [95% CI, 1.59-3.44]), prior episode of pneumonia (OR, 3.15 [95% CI, 1.83-5.42]), symptoms starting 4 to 7 days prior to seeking ED care (vs starting 0-3 days before seeking care: OR

Published
2022

3. Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection

Author

Pediatría, Pediatria, Funk, Anna L., Kuppermann, Nathan, Florin, Todd A., Tancredi, Daniel J., Xie, Jianling, Kim, Kelly, Finkelstein, Yaron, Neuman, Mark I., Salvadori, Marina I., Yock-Corrales, Adriana, Breslin, Kristen A., Ambroggio, Lilliam, Chaudhari, Pradip P., Bergmann, Kelly R., Gardiner, Michael A., Nebhrajani, Jasmine R., Campos, Carmen, Ahmad, Fahd A., Sartori, Laura F., Navanandan, Nidhya, Kannikeswaran, Nirupama, Caperell, Kerry, Morris, Claudia R., Mintegi Raso, Santiago, Gangoiti, Iker, Sabhaney, Vikram J., Plint, Amy C., Klassen, Terry P., Avva, Usha R., Shah, Nipam P., Dixon, Andrew C., Lunoe, Maren M., Becker, Sarah M., Rogers, Alexander J., Pavlicich, Viviana, Dalziel, Stuart R., Payne, Daniel C., Malley, Richard, Borland, Meredith L., Morrison, Andrea K., Bhatt, Maala, Rino, Pedro B., Beneyto Ferre, Isabel, Eckerle, Michelle, Kam, April J., Chong, Shu-Ling, Palumbo, Laura, Kwok, Maria Y., Cherry, Jonathan C., Poonai, Naveen, Waseem, MD; Norma-Jean Simon, MPH, Waseem, Muhammad, Simon, Norma-Jean, Freedman, Stephen B., Pediatric Emergency Research Network–COVID-19 Study Team, Pediatría, Pediatria, Funk, Anna L., Kuppermann, Nathan, Florin, Todd A., Tancredi, Daniel J., Xie, Jianling, Kim, Kelly, Finkelstein, Yaron, Neuman, Mark I., Salvadori, Marina I., Yock-Corrales, Adriana, Breslin, Kristen A., Ambroggio, Lilliam, Chaudhari, Pradip P., Bergmann, Kelly R., Gardiner, Michael A., Nebhrajani, Jasmine R., Campos, Carmen, Ahmad, Fahd A., Sartori, Laura F., Navanandan, Nidhya, Kannikeswaran, Nirupama, Caperell, Kerry, Morris, Claudia R., Mintegi Raso, Santiago, Gangoiti, Iker, Sabhaney, Vikram J., Plint, Amy C., Klassen, Terry P., Avva, Usha R., Shah, Nipam P., Dixon, Andrew C., Lunoe, Maren M., Becker, Sarah M., Rogers, Alexander J., Pavlicich, Viviana, Dalziel, Stuart R., Payne, Daniel C., Malley, Richard, Borland, Meredith L., Morrison, Andrea K., Bhatt, Maala, Rino, Pedro B., Beneyto Ferre, Isabel, Eckerle, Michelle, Kam, April J., Chong, Shu-Ling, Palumbo, Laura, Kwok, Maria Y., Cherry, Jonathan C., Poonai, Naveen, Waseem, MD; Norma-Jean Simon, MPH, Waseem, Muhammad, Simon, Norma-Jean, Freedman, Stephen B., and Pediatric Emergency Research Network–COVID-19 Study Team

Abstract

IMPORTANCE Little is known about the risk factors for, and the risk of, developing post-COVID-19 conditions (PCCs) among children. OBJECTIVES To estimate the proportion of SARS-CoV-2-positive children with PCCs 90 days after a positive test result, to compare this proportion with SARS-CoV-2-negative children, and to assess factors associated with PCCs. DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study, conducted in 36 emergency departments (EDs) in 8 countries between March 7, 2020, and January 20, 2021, included 1884 SARS-CoV-2-positive children who completed 90-day follow-up; 1686 of these children were frequency matched by hospitalization status, country, and recruitment date with 1701 SARS-CoV-2-negative controls. EXPOSURE SARS-CoV-2 detected via nucleic acid testing. MAIN OUTCOMES AND MEASURES Post-COVID-19 conditions, defined as any persistent, new, or recurrent health problems reported in the 90-day follow-up survey. RESULTS Of 8642 enrolled children, 2368 (27.4%) were SARS-CoV-2 positive, among whom 2365 (99.9%) had index ED visit disposition data available; among the 1884 children (79.7%) who completed follow-up, the median age was 3 years (IQR, 0-10 years) and 994 (52.8%) were boys. A total of 110 SARS-CoV-2-positive children (5.8%; 95% CI, 4.8%-7.0%) reported PCCs, including 44 of 447 children (9.8%; 95% CI, 7.4%-13.0%) hospitalized during the acute illness and 66 of 1437 children (4.6%; 95% CI, 3.6%-5.8%) not hospitalized during the acute illness (difference. 5.3%; 95% CI, 2.5%-8.5%). Among SARS-CoV-2-positive children, the most common symptom was fatigue or weakness (21 [1.1%]). Characteristics associated with reporting at least 1 PCC at 90 days included being hospitalized 48 hours or more compared with no hospitalization (adjusted odds ratio [aOR], 2.67 [95% CI, 1.63-4.38]); having 4 or more symptoms reported at the index ED visit compared with 1 to 3 symptoms (4-6 symptoms: aOR, 2.35 [95% CI, 1.28-4.31]; >= 7 symptoms: aOR, 4.59 [95% CI

Published
2022

4. Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection

Author

Funk, Anna L., Kuppermann, Nathan, Florin, Todd A., Tancredi, Daniel J., Xie, Jianling, Kim, Kelly, Finkelstein, Yaron, Neuman, Mark I., Salvadori, Marina I., Yock-Corrales, Adriana, Breslin, Kristen A., Ambroggio, Lilliam, Chaudhari, Pradip P., Bergmann, Kelly R., Gardiner, Michael A., Nebhrajani, Jasmine R., Campos, Carmen, Ahmad, Fahd A., Sartori, Laura F., Navanandan, Nidhya, Kannikeswaran, Nirupama, Caperell, Kerry, Morris, Claudia R., Mintegi Raso, Santiago, Gangoiti, Iker, Sabhaney, Vikram J., Plint, Amy C., Klassen, Terry P., Avva, Usha R., Shah, Nipam P., Dixon, Andrew C., Lunoe, Maren M., Becker, Sarah M., Rogers, Alexander J., Pavlicich, Viviana, Dalziel, Stuart R., Payne, Daniel C., Malley, Richard, Borland, Meredith L., Morrison, Andrea K., Bhatt, Maala, Rino, Pedro B., Beneyto Ferre, Isabel, Eckerle, Michelle, Kam, April J., Chong, Shu-Ling, Palumbo, Laura, Kwok, Maria Y., Cherry, Jonathan C., Poonai, Naveen, Waseem, MD, Norma-Jean Simon, MPH, Waseem, Muhammad, Simon, Norma-Jean, Freedman, Stephen B., and Pediatric Emergency Research Network–COVID-19 Study Team

Subjects
COVID-19, outcomes
Abstract

IMPORTANCE Little is known about the risk factors for, and the risk of, developing post-COVID-19 conditions (PCCs) among children. OBJECTIVES To estimate the proportion of SARS-CoV-2-positive children with PCCs 90 days after a positive test result, to compare this proportion with SARS-CoV-2-negative children, and to assess factors associated with PCCs. DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study, conducted in 36 emergency departments (EDs) in 8 countries between March 7, 2020, and January 20, 2021, included 1884 SARS-CoV-2-positive children who completed 90-day follow-up; 1686 of these children were frequency matched by hospitalization status, country, and recruitment date with 1701 SARS-CoV-2-negative controls. EXPOSURE SARS-CoV-2 detected via nucleic acid testing. MAIN OUTCOMES AND MEASURES Post-COVID-19 conditions, defined as any persistent, new, or recurrent health problems reported in the 90-day follow-up survey. RESULTS Of 8642 enrolled children, 2368 (27.4%) were SARS-CoV-2 positive, among whom 2365 (99.9%) had index ED visit disposition data available; among the 1884 children (79.7%) who completed follow-up, the median age was 3 years (IQR, 0-10 years) and 994 (52.8%) were boys. A total of 110 SARS-CoV-2-positive children (5.8%; 95% CI, 4.8%-7.0%) reported PCCs, including 44 of 447 children (9.8%; 95% CI, 7.4%-13.0%) hospitalized during the acute illness and 66 of 1437 children (4.6%; 95% CI, 3.6%-5.8%) not hospitalized during the acute illness (difference. 5.3%; 95% CI, 2.5%-8.5%). Among SARS-CoV-2-positive children, the most common symptom was fatigue or weakness (21 [1.1%]). Characteristics associated with reporting at least 1 PCC at 90 days included being hospitalized 48 hours or more compared with no hospitalization (adjusted odds ratio [aOR], 2.67 [95% CI, 1.63-4.38]); having 4 or more symptoms reported at the index ED visit compared with 1 to 3 symptoms (4-6 symptoms: aOR, 2.35 [95% CI, 1.28-4.31]; >= 7 symptoms: aOR, 4.59 [95% CI, 2.50 8.44]); and being 14 years of age or older compared with younger than 1 year (aOR, 2.67 [95% CI, 1.43-4.99]). SARS-CoV-2-positive children were more likely to report PCCs at 90 days compared with those who tested negative, both among those who were not hospitalized (55 of 1295 [4.2%; 95% CI, 3.2%-5.5%] vs 35 of 1321[2.7%; 95% CI, 1.9%-3.7%]; difference, 1.6% [95% CI, 0.2%-3.0%]) and those who were hospitalized (40 of 391[10.2%; 95% CI, 7.4%-13.7%] vs 19 of 380 [5.0%; 95% CI, 3.0%-7.7%]; difference, 5.2% [95% CI, 1.5%-9.1%]). In addition, SARS-CoV-2 positivity was associated with reporting PCCs 90 days after the index ED visit (aOR, 1.63 [95% CI, 1.14-2.35]), specifically systemic health problems (eg, fatigue, weakness, fever; aOR, 2.44 [95% CI, 1.19-5.00]). CONCLUSIONS AND RELEVANCE In this cohort study, SARS-CoV-2 infection was associated with reporting PCCs at 90 days in children. Guidance and follow-up are particularly necessary for hospitalized children who have numerous acute symptoms and are older. This studywas supported by grants from the Canadian Institutes of Health Research (operating grant: COVID-19-clinical management); the Alberta Health Services-University of Calgary-Clinical Research Fund; the Alberta Children's Hospital Research Institute; the COVID-19 Research Accelerator Funding Track (CRAFT) Program at the University of California, Davis; and the Cincinnati Children's Hospital Medical Center Division of Emergency Medicine Small Grants Program. Dr Funk is supported by the University of Calgary Eyes-High PostDoctoral Research Fund. Dr Freedman is supported by the Alberta Children's Hospital Foundation Professorship in Child Health andWellness.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results